CML Virtual Journal Club | 24-Month Follow-Up of the Phase III Randomized ENESTnd Trial |
Expert perspectives with Giuseppe Saglio, MD, and Juan Luis Steegmann, MD, PhD.
This independent medical education activity features an expert interview with Giuseppe Saglio, MD, and Juan Luis Steegmann, MD, PhD, focusing on observations from an important publication reporting on the 24-month follow-up of the phase III randomized ENESTnd trial comparing nilotinib and imatinib for the treatment of patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML). (Kantarjian HM, et al. Lancet Oncol. 2011;12(9):841-851)
Drs Saglio and Steegmann briefly discuss the analysis presented in this publication and how this information will impact clinical practice. |
 Learning Objectives | After successful completion of this educational activity, participants should be able to:
- Discuss optimal treatment strategies for newly diagnosed chronic myeloid leukemia, and compare imatinib with second-generation tyrosine kinase inhibitors in the management of patients with CML
- Evaluate the impact of recent clinical trial data surrounding the management of patients with newly diagnosed CML on clinical practice
|
|
Audience | This educational activity is designed for hematologists, oncologists, and other healthcare professionals involved and/or interested in the management of patients with hematologic malignancies. The information on this site is intended for healthcare professionals based outside of the United States. |
|
|
Support | Support for this educational activity is provided by Novartis Oncology.
|
|
Disclosures |
Disclosure of Conflicts of Interest
prIME Oncology assesses conflicts of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of activities. All relevant conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
Disclosure of Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
|
|
|
|
Featured Experts |
 |
|
Giuseppe Saglio, MD
University of Turin
Turin, Italy
|
| |
|
|
 |
|
Juan Luis Steegmann, MD, PhD
Hospital Universitario de la Princesa
Madrid, Spain
|
|
Activity Date | This Webcast is available from 5 December 2011 to 5 December 2012. |
|
